Feed - Buzzberg

12:30
Aug 06 ◎

ZTS FY2026 Q2 Watch

Zoetis Inc. (ZTS) FY2026 Q2 Earnings Call

ZTS ▾

Kristin Peck

Management acknowledged significant downward pressure on the US companion animal business, cutting FY2026 guidance substantially. The tone is defensive, focused on share protection via price investments rather than growth.

"we are going to be aggressive as we think about growth to net investments in rebates and pricing and you know pet owner point of sale to make sure that we protect our volume in a market that may not be growing as fast."

ZTS WATCH

HIGH

12:30
May 07 ◎

ZTS FY2026 Q1 Watch

Zoetis Inc. (ZTS) FY2026 Q1 Earnings Call

NEOG ZTS ▾

Kristen Peck

The acquisition diversifies Zoetis into livestock genetics, a growing segment, and signifies they are deploying capital into new growth areas.

"we announced an agreement to acquire Neogen's animal genomics business, expanding our capabilities in livestock genetics."

NEOG WATCH

Whitney Joseph

Guidance was revised downward significantly due to a weaker-than-expected Q1, where US companion animal sales declined sharply due to consumer price sensitivity, increased competition, and reduced clinic traffic. The company is taking a cautious stance for the rest of the year.

"For the full year, on an organic operational basis, we expect revenue growth of 2% to 5% and adjusted net income growth of 2% to 6%."

ZTS WATCH

HIGH

13:30
Feb 12 ◎

ZTS FY2025 Q4 Watch

Zoetis Inc. (ZTS) FY2025 Q4 Earnings Call

ELAN ZTS IDXX MRK ▾

Kristin Peck

Management notes that US owner economics are being squeezed by escalating veterinary clinic prices, which is driving a decline in routine care visits and accelerating a shift toward emergency/urgent care and value-focused, alternative care models. — A structural slowdown in routine veterinary visits in the US could dampen the volume of products sold through traditional clinics, pressuring companies with high US companion-animal exposure and shifting demand toward retail/online channels and urgent care centers.

"We continue to see some economic pressure on Gen Z and millennial pet owners, which has contributed to a decline in therapeutic visits and doses. At the same time, emergency and urgent care continue to show strength"

ELAN WATCH IDXX WATCH

Kristin Peck

Management's tone is cautiously neutral. They acknowledge persistent US macro pressure and intensifying competition but expect conditions to gradually improve through 2026. Guidance of 3-5% revenue growth reflects a prudent outlook in line with near-term headwinds.

"This outlook reflects our confidence and our ability to execute across the portfolio while navigating macroeconomic and competitive pressure, which we expect to moderate as the year progresses."

ZTS WATCH

Kristin Peck

In dermatology, management acknowledges pressure from competition and promotional activity on Apoquel, but notes that switching from Cytopoint and Apoquel chewable has been limited, indicating brand loyalty within the franchise and that the competitive threat is primarily on new patient starts. — The competitive share erosion in the dermatology market is concentrated on acquiring new patients; the inability to convert existing patients limits the potential upside for a new entrant like Merck's Zenrelia and points to a slower, more costly ramp-up.

"While we have seen some impact on Apricol share due to competition, switch from Cytopoint and Apricol-Truable has been limited."

MRK WATCH

HIGH

Feed — Buzzberg